Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 20/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.72 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246505 | 1.00 | CHRNA7 (0.72) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4245238 | 0.98 | CHRNA7 (0.71) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4238544 | 0.98 | CHRNA7 (0.71) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4249952 | 0.94 | CHRNA7 (0.69) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4246802 | 0.92 | CHRNA7 (0.69) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4244151 | 0.91 | CHRNA7 (0.70) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4250650 | 0.90 | CHRNA7 (0.71) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL13878617 | 0.90 | CHRNA7 (0.70) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4245830 | 0.88 | CHRNA7 (0.72) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4242400 | 0.88 | CHRNA7 (0.75) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885KCNH2 815/4885CHRNA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.